瑞舒伐他汀钙片对冠心病合并心力衰竭患者的治疗效果

Effect of Rosuvastatin Calcium Tablets in the treatment of patients with coronary heart disease and heart failure

  • 摘要: 目的 分析瑞舒伐他汀钙片对冠心病合并心力衰竭患者的血脂指标、心功能与炎症因子水平的影响。 方法 选择收治的75例冠心病合并心力衰竭患者为研究对象,并分为对照组和实验组,分别在常规治疗基础上应用常规剂量瑞舒伐他汀钙、高剂量瑞舒伐他汀钙治疗。比较2组临床治疗效果,治疗前后血脂指标、心功能、炎症因子水平及不良反应发生情况。 结果 实验组治疗优良率为97.30%, 显著高于对照组的78.95%(P<0.05)。治疗前, 2组高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、总胆固醇(TC)比较,差异无统计学意义(P>0.05); 治疗后,实验组LDL-C显著高于对照组,HDL-C、TG、TC显著低于对照组(P<0.05)。治疗前, 2组左室收缩期内径(LVESD)、左心室射血分数(LVEF)、左室舒张末期内径(LVEDD)比较无显著差异(P>0.05); 治疗后,实验组LVEF显著高于对照组, LVESD、LVEDD显著低于对照组(P<0.05)。治疗前,2组脑钠肽(BNP)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)水平比较,差异无统计学意义(P>0.05); 治疗后,实验组上述指标均显著低于对照组(P<0.05)。2组不良反应总发生率比较,差异无统计学意义(P>0.05)。 结论 在冠心病合并心力衰竭治疗中应用瑞舒伐他汀钙片,可改善患者血脂指标,强化心功能,减轻炎症反应,不良反应较少。

     

    Abstract: Objective To analyze the effects of Rosuvastatin Calcium Tablets on blood lipid indexes, cardiac function and inflammatory factor levels in patients with coronary heart disease and heart failure. Methods A total of 75 patients with coronary heart disease and heart failure included in the study were selected as research objects, and were divided into control and experimental groups, given normal dose of Rosuvastatin Calcium Tablets and high-dose of Rosuvastatin Calcium Tablets based on the conventional treatment, respectively. The clinical treatment effect, blood lipid indexes, cardiac function, inflammatory factor levels, and occurrence of adverse reactions of two groups were compared before and after treatment. Results The excellent rate of treatment in the experimental group was significantly higher than that in the control group(97.30% vs. 78.95%, P<0.05). Before treatment, there were no significant differences between the two groups in high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C), triacylglycerol(TG), and total cholesterol(TC)(P>0.05). After treatment, LDL-C in the experimental group was significantly higher than that in the control group, and HDL-C, TG, and TC were significantly lower than those in the control group(P<0.05). Before treatment, there were no significant differences in left ventricular systolic diameter(LVESD), left ventricular ejection fraction(LVEF), and left ventricular end diastolic diameter(LVEDD)between the two groups(P>0.05). After treatment, LVEF in - the experimental group was higher, and LVESD as well as LVEDD were significantly lower than the control group(P<0.05). Before treatment, the levels of brain natriuretic peptide(BNP), tumor necrosis factor-α(TNF-α), and high sensitivity C reactive protein(hs-CRP)in the two groups showed no significant differences(P>0.05). After treatment, the levels of the above indicators in the experimental group were significantly lower than those in the control group(P<0.05). The total incidence of adverse reactions between the two groups showed no significant difference(P>0.05). Conclusion The application of Rosuvastatin Calcium Tablets in the treatment of coronary heart disease and heart failure can improve the blood lipid index of patients, strengthen their heart function, relieve inflammatory response, and has less adverse reactions.

     

/

返回文章
返回